Literature DB >> 6122483

Adrenergic mechanisms in control of plasma lipid concentrations.

J L Day, J Metcalfe, C N Simpson.   

Abstract

The mechanisms of the changes in plasma lipids concentrations observed after beta-blockade were examined in 53 patients with hypertension receiving treatment with atenolol, metoprolol, propranolol, and oxprenolol in a randomised cross-over trial. Significant increases in mean plasma total and very-low-density lipoprotein (VLDL) triglyceride and reductions in high-density lipoprotein (HDL) cholesterol and free fatty acids concentrations wer observed with all four drugs, the increase in plasma triglyceride concentration being greatest after propranolol and oxprenolol. No significant changes were observed in total of LDL cholesterol concentrations, but HDL:LDL ratios and HDL cholesterol as a proportion of total cholesterol fell significantly. Thus plasma lipid concentrations should be monitored after three to six months of long-term treatment. Changes in triglyceride, HDL cholesterol and free fatty acid concentrations were associated with a highly significant reduction in clearance of soya oil (Intralipid) in 25 patients studied but were unrelated to changes in blood pressure. The fall in HDL cholesterol and rise in free fatty acid concentrations were significantly less in those with initially reduced HDL cholesterol or raised free fatty acid concentrations respectively. It is proposed that unopposed alpha stimulation inhibits lipoprotein lipase with a subsequent rise in plasma triglyceride and fall in HDL cholesterol concentration. Analysis of the relation between pretreatment concentrations and subsequent changes suggests that excessive alpha stimulation may impair production of HDL cholesterol in those with low HDL cholesterol concentrations before treatment. Subtle catecholamine-mediated changes in plasma lipid concentrations might provide a mechanism for the relation between stress and the development of cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6122483      PMCID: PMC1496811          DOI: 10.1136/bmj.284.6323.1145

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  19 in total

1.  SERUM LIPIDS AND CONJUNCTIVAL CIRCULATION AFTER FAT INGESTION IN MEN EXHIBITING TYPE-A BEHAVIOR PATTERN.

Authors:  M FRIEDMAN; R H ROSENMAN; S BYERS
Journal:  Circulation       Date:  1964-06       Impact factor: 29.690

2.  [On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins].

Authors:  M BURSTEIN; J SAMAILLE
Journal:  Clin Chim Acta       Date:  1960-07       Impact factor: 3.786

3.  Association of specific overt behavior pattern with blood and cardiovascular findings; blood cholesterol level, blood clotting time, incidence of arcus senilis, and clinical coronary artery disease.

Authors:  M FRIEDMAN; R H ROSENMAN
Journal:  J Am Med Assoc       Date:  1959-03-21

4.  Determination of the intravenous fat tolerance test with intralipid by nephelometry.

Authors:  B Lewis; L Boberg; M Mancini; L A Carlson
Journal:  Atherosclerosis       Date:  1972 Jan-Feb       Impact factor: 5.162

5.  Application of a new intravenous fat tolerance test in the study of hypertriglyceridaemia in man.

Authors:  J Boberg; L A Carlson; D Hallberg
Journal:  J Atheroscler Res       Date:  1969 Mar-Apr

6.  Labetalol and lipids.

Authors:  R J McGonigle; L Williams; M J Murphy; V Parsons
Journal:  Lancet       Date:  1981-01-17       Impact factor: 79.321

7.  Studies on the effects of propanolol on plasma catecholamine levels in patients with essential hypertension.

Authors:  K H Rahn; H W Gierlichs; G Planz; R Planz; M Schols; W Stephany
Journal:  Eur J Clin Invest       Date:  1978-06       Impact factor: 4.686

8.  Coronary heart disease in Western Collaborative Group Study. Final follow-up experience of 8 1/2 years.

Authors:  R H Rosenman; R J Brand; D Jenkins; M Friedman; R Straus; M Wurm
Journal:  JAMA       Date:  1975-08-25       Impact factor: 56.272

9.  Metabolic consequences of atenolol and propranolol in treatment of essential hypertension.

Authors:  J L Day; N Simpson; J Metcalfe; R L Page
Journal:  Br Med J       Date:  1979-01-13

10.  Effect of propranolol and prazosin on blood lipids. The Oslo Study.

Authors:  P Leren; P O Foss; A Helgeland; I Hjermann; I Holme; P G Lund-Larsen
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

View more
  30 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia.

Authors:  Yuji Kadoi; Shigeru Saito
Journal:  J Anesth       Date:  2010-02       Impact factor: 2.078

Review 3.  Effects of acebutolol on the serum lipid profile.

Authors:  A Clucas; N Miller
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts.

Authors:  H Yoshida; M Suzukawa; T Ishikawa; H Shige; E Nishio; H Hosoai; M Ayaori; H Nakamura
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 5.  Profile of an ideal antianginal agent.

Authors:  E J Lazar; W H Frishman
Journal:  Drugs       Date:  1989       Impact factor: 9.546

6.  Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise.

Authors:  L Gullestad; L O Dolva; S E Kjeldsen; I Eide; J Kjekshus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

7.  Failure of the nonselective beta-blocker propranolol to affect lipoprotein lipase gene expression in the rat.

Authors:  I Gouni-Berthold; K Oka; H K Berthold; L Chan
Journal:  Lipids       Date:  1997-09       Impact factor: 1.880

8.  Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects.

Authors:  S Rössner; L Weiner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Beta-blocker induced changes in the cholesterol: high-density lipoprotein cholesterol ratio and risk of coronary heart disease.

Authors:  B G Woodcock; N Rietbrock
Journal:  Klin Wochenschr       Date:  1984-09-17

10.  Beta adrenoceptor blockade and responses of serum lipids to a meal and to exercise.

Authors:  N R Peden; R J Dow; T E Isles; B T Martin
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.